TD Cowen Rates Humacyte (HUMA) buy, $1.25 Price Target

TD Cowen maintains its buy rating on Humacyte with a $1.25 target, a 48.99% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 11:01 AM EDT · Updated Jun 23, 2026, 1:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen rated Humacyte, Inc. ($HUMA) "buy" with a $1.25 price target on June 17, 2026.

Since the rating, $HUMA is down 27.8% after 1 week, down 30.9% after 1 month and down 55.7% to date (from the $0.97 close on Jun 17, 2026).

HUMA Humacyte, Inc.

$0.43 -55.67% year to date

Daily close · Oct 16, 2026

Key Points

TD Cowen reiterated its buy rating on Humacyte, Inc. (HUMA) with a price target of $1.25 on June 17, 2026.
TD Cowen's $1.25 price target implies 48.99% upside from Humacyte, Inc.'s ($HUMA) current $0.84 share price.
Humacyte shares are trading near $1.03 with a market cap of about $277.7 million and a beta of 2.457.
Insider buying was notable with multiple executives purchasing 80,000 shares each on June 11, 2026.

Get $HUMA trade alerts by text

We text you when insiders, Congress or big funds trade $HUMA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humacyte, Inc. alert may contain errors. Disclosures

TD Cowen has reiterated its buy rating on Humacyte, Inc. (NasdaqGS: HUMA) as of June 17, 2026. Analyst Joshua Jennings set a price target of $1.25, while the stock is currently trading near $1.03.

Other Institutional Activity in Humacyte

Several institutional investors have been adjusting their positions in Humacyte. BlackRock, Inc. increased its holdings by 971,836 shares, bringing its total to 12,316,955 shares, valued at approximately $7.47 million. Vanguard Capital Management LLC made a significant move by adding 7,158,162 shares, reaching a total of 7,158,162 shares worth about $4.35 million. Antipodes Partners Ltd also boosted its stake dramatically by 5,712,102 shares to a total of 5,723,750 shares, valued at $3.47 million. Meanwhile, Geode Capital Management, LLC slightly reduced its position by 62,328 shares, leaving it with 3,658,108 shares valued at $2.22 million.

Humacyte, Inc. Stock Up 43.3%

Shares of Humacyte, Inc. (NasdaqGS: HUMA) are trading near $1.03. The company has a market capitalization of approximately $277.7 million and a beta of 2.457, indicating higher volatility compared to the broader market. The stock's 52-week range is between $0.55 and $2.84. Humacyte's 50-day moving average is $0.97, while its 200-day moving average stands at $1.20. The company shows a current ratio of 3.93 and a quick ratio of 3.03, but a high debt-to-equity ratio of 572.1.

12-month forecast

$HUMA price target

Humacyte, Inc. daily closes and this analyst's $1.25 target. Not advice.

Recent Earnings

Humacyte's revenue was $2.02 million, reflecting a slight decline in growth. The company's EPS was reported at -$0.60, with no meaningful P/E ratio due to lack of profitability. The return on equity stands at -4.09%, and the net margin is zero. Investors can expect the next earnings report on August 10, 2026.

Insider Buying and Selling at Humacyte, Inc.

There was notable insider buying activity at Humacyte on June 11, 2026. Several executives, including CEO Dr. Laura Niklason, purchased 80,000 shares each. Other insiders such as Susan Richards Windham-Bannister, Keith Anthony Jones, Max Wallace, Michael Constantino, and Kathleen Sebelius also acquired 80,000 shares each.

Analysts Set New Price Targets

On June 17, 2026, TD Cowen maintained its buy rating on Humacyte with a price target of $1.25. Other analysts have also shown confidence in the stock. On June 11, 2026, HC Wainwright & Co. maintained a buy rating with a $4.00 price target. BTIG reiterated its buy rating with a $2.00 target on June 8, 2026. The consensus among analysts is a buy rating, with an average price target of $2.10 based on five analyst opinions.

About Humacyte, Inc.

Humacyte, Inc. is a biotechnology company based in Durham, North Carolina. It specializes in developing and manufacturing bioengineered human tissues for various medical applications. The company focuses on creating human acellular vessels (HAVs) for vascular repair, replacement, and reconstruction. These products aim to minimize immune rejection and foreign body response. Founded in 2004, Humacyte is led by CEO Dr. Laura E. Niklason and employs about 184 people.

Bottom Line

TD Cowen's reiterated buy rating and price target of $1.25 reflect ongoing confidence in Humacyte's potential. The stock's performance, insider buying, and analyst ratings suggest attention from both institutional and individual investors. As a biotechnology firm, Humacyte's developments in bioengineered tissues are closely watched, though the data from analyst ratings and insider transactions are backward-looking and do not necessarily indicate future performance.